All News
DMARD Effects on COVID-19 Outcomes
Sparks and colleagues have published data from the Global Rheumatology Alliance noting that among rheumatoid arthritis (RA) patients afflicted with COVID-19 infection, there was little influence of their baseline biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drug
Read Article
RheumNow Podcast – World Going to Pot (7.23.2021)
Bicycles, Tramadol, biologics - these are but a few of my favorites things in today's broadcast. Join me as I review the news and journal articles from this past week on RheumNow.com.
Read Article
Fracture Risk with Low Dose Steroid
A large RA cohort analysis shows that low-dose glucocorticoid therapy in rheumatoid arthritis (RA) patients may carry an increased risk of vertebral osteoporotic (OP) fractures.
Read Article
Tofacitinib Efficacy in Ankylosing Spondylitis
Deodhar and colleagues have published the results of a study showing that in adult patients with active ankylosing spondylitis (AS), oral tofacitinib was effective (versus placebo) and is safe.
Read Article
Growing Cannabis Use in Arthritis Patients
The National Databank for Rheumatic Diseases reports a significant increased in cannabis use amongst arthritis patients between 2014-2019, suggesting patients are more frequently engaged in self-management of pain and the unmet need for a pain relieving, opioid-sparing alternative.
Read Article
New-Onset IBD and IL-17 Inhibitors: What Is the Risk?
Patients with inflammatory/autoimmune diseases who initiated treatment with interleukin (IL)-17 inhibitors did not have a higher risk for the development of inflammatory bowel disease (IBD), but only after taking into account the severity of their underlying disease, French investigators reported
Read Article
FDA Approves IVIG in Dermatomyositis
The U.S. Food and Drug Administration (FDA) has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM).
Read Article
Canakinumab Fails to Improve COVID-19 Survival
JAMA has published the findings of trial wherein the anti–interleukin-1β antibody canakinumab (CAN) failed to improve survival in patients hospitalized with severe COVID-19.
Read Article
ACR/Vasculitis Foundation Guideline for Giant Cell Arteritis and Takayasu Arteritis
The ACR and the Vasculitis Foundation have published their evidence-based recommendations and expert guidance for the management of GCA and Takayasu arteritis. These recommendations address a variety of clinical questions and scenarios including diagnostic testing, imaging, treatments, and surgical interventions. Recommendations for GCA and TAK include support for the use of glucocorticoid-sparing immunosuppressive agents and the use of imaging to identify large vessel involvement. Recommendations for TAK include the use of glucocorticoids as initial therapy.
Read Article
Impact of Nail Psoriasis on Psoriatic Arthritis
Mease and colleagues have shown that psoriatic arthritis (PsA) patients with nail involvement have worse disease and outcomes than those without nail psoriasis.
Read Article
RheumNow Podcast – What Not to Do (7.16.2021)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read Article
ACR/Vasculitis Foundation 2021 Guidelines for ANCA–Associated Vasculitis
Chung et al have published the 2021 treatment guielines for the management of antineutrophil cytoplasmic antibody–associated vasculitis, including granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis. These guidelines are put forth by the ACR and the Vasculitis Foundation as benchmark guidance to assist health care professionals in managing AAV.
Read Article
Slow Steroid Tapering Succeeds in SLE
Gradual withdrawal of glucocorticoids was successful among patients with systemic lupus erythematosus (SLE) after 2 years of clinically quiescent disease, without an increased likelihood of flares, Canadian researchers reported.
Read Article
Potential Birth Defects with Hydroxychloroquine
Hydroxychloroquine (HCQ) is one of the safest meds used in rheumatology, but there is new claims data suggesting a small increase in the risk of malformations associated with first-trimester HCQ use.
Read Article
Rare Myocarditis Risk following COVID-19 Vaccine
MMWR review of the risk of myocarditis and pericarditis reports a June 23, 2021 recommendation by the Advisory Committee on Immunization Practices that the benefits of COVID-19 vaccination clearly outweighed the risks of myocarditis after vaccination.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
